Free Access
Issue
Med Sci (Paris)
Volume 17, Number 12, Décembre 2001
Page(s) 1297 - 1305
Section Articles de Synthèse
DOI https://doi.org/10.1051/medsci/200117121297
Published online 15 December 2001
  1. Consensus development conference. Prophylaxis and treatment of osteoporosis. Am J Med 1991; 90 : 107–10. [Google Scholar]
  2. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996; 11 : 1043–51. [Google Scholar]
  3. Oursler MJ, Osdoby P, Pyfferoen J, et al. Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci USA 1991; 88 : 6613–7. [Google Scholar]
  4. Melton LJ. How many women have osteoporosis now? J Bone Miner Res 1995; 10 : 175–7. [Google Scholar]
  5. Cooper C, Campion G, Melton LJ. Hip fractures in the elderly : a world-wide projection. Osteoporos Int 1992; 2 : 285–9. [Google Scholar]
  6. Melton LJ. Differing patterns of osteoporosis across the world. In : Chesnut CH, ed. New dimensions in osteoporosis in the 1990s. Asia Pacific Conference Series n° 125. Hong Kong : Excerpta Medica, 1991 : 13–8. [Google Scholar]
  7. Schurch MA, Rizzoli R, Mermillod B, et al. A prospective study on socioeconomic aspects on fracture of the proximal femur. J Bone Miner Res 1996; 11 : 1935–42. [Google Scholar]
  8. Kellie SE, Brody JA. Sex-specific and racespecific hip fractures rates. Am J Publ Health 1990; 80 : 326–8. [Google Scholar]
  9. Marotelli RA, Berkman LF, Cooney LM, et al. Decline in physical function following hip fracture. J Am Geriatr Soc 1992; 40 : 861–6. [Google Scholar]
  10. Kanis JA, McCloskey EV. Epidemiology of vertebral osteoporosis. Bone 1992; 13 : S1–10. [Google Scholar]
  11. Cooper C, Atkinson EJ, O’Fallen WM, et al. Incidence of clinically diagnosed vertebral fractures : a population-based study in Rochester, Minnesota, 1985–1989. J Bone Miner Res 1992; 7 : 221–7. [Google Scholar]
  12. Melton LJ, Lane AW, Cooper C, et al. Prevalence and incidence of vertebral deformities. Osteoporos Int 1993; 3 : 113–9. [Google Scholar]
  13. Owen RA, Melton LJ, Johnson KA, et al. Incidence of Colls’ fractures in a north american community. Am J Publ Health 1982; 72 : 605–7. [Google Scholar]
  14. Cooper C, Melton LJ. Epidemiology of osteoporosis. Trends Endocrinol Metab 1992; 314 : 224–9. [Google Scholar]
  15. Pocock NA. Genetic determinants of bone mass in adults. J Clin Invest 1987; 80 : 706–10. [Google Scholar]
  16. Cummings SR, Cauley J, Palermo L, et al. Racial differences in hip axis lengths might explain racial differences in rates of hip fracture. Osteoporos Int 1994; 4 : 226–9. [Google Scholar]
  17. Johnell O, Gullberg B, Kanis JA, et al. Risk factors for hip fracture in European women : the MEDOS study. J Bone Miner Res 1995; 10 : 1802–15. [Google Scholar]
  18. Ross PD, Davis JW, Epstein RS, Wasnish RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991; 114 : 914–23. [Google Scholar]
  19. Wasnich RD, Davis JW, Ross PD. Spine fracture risk is predicted by non-spine fractures. Osteoporos Int 1994; 4 : 1–5. [Google Scholar]
  20. Delmas PD, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 2000; suppl 6 : S2–17. [Google Scholar]
  21. Garnero P, Shih WJ, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79 : 1693–700. [Google Scholar]
  22. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas P. Biochemical markers of bone turnover predict postmenopausal forearm bone loss over 4 years : the OFELY study. J Bone Miner Res 1999; 14 : 1614–21. [Google Scholar]
  23. Hans D, Dargent-Molina P, Schott AM, et al. Ultrasonographic heel measurements to predict hip fracture in elderly women : the EPIDOS prospective study. Lancet 1996; 348 : 511–4. [Google Scholar]
  24. Kanis JA, Melton LJ, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9 : 1137–41. [Google Scholar]
  25. Gardsell P, Johnell O, Nilsson BE. The predictive value of bone loss for fragility fractures in women : a longitudinal study over 15 years. Calcif Tissue Int 1991; 49 : 90–4. [Google Scholar]
  26. Black DM, Cummings SR, Genant HK, et al. Axial and appendicular bone density predict fractures in older women. J Bone Miner Res 1992; 7 : 633–8. [Google Scholar]
  27. Cummings SR, Black DM, Newitt MC,et al. Bone density at various sites for prediction of hip fractures. Lancet 1993; 341 : 72–5. [Google Scholar]
  28. Hesley PP, Shepard KA, Jenkins DK, et al. Monitoring estrogen replacement therapy and identifying rapid bone losers with an immunoassay for deoxypyridinoline. Osteoporos Int 1998; 8 : 159–64. [Google Scholar]
  29. Cauley JA, Seeley DJ, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995; 122 : 9–16. [Google Scholar]
  30. Lufkin EG, Wahner HW, O’Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117 : 1–9. [Google Scholar]
  31. Felson DT, Zhang Y, Nannan MT, et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329 : 114–6. [Google Scholar]
  32. Collaborative Group on Hormonal therapy in breast cancer. Breast cancer and hormone replacement therapy : collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350 : 1047–59. [Google Scholar]
  33. Lin JH. Bisphosphonates : a review of their pharmacokinetic properties. Bone 1996; 18 : 75–85. [Google Scholar]
  34. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13 : 581–9. [Google Scholar]
  35. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322 : 1265–71. [Google Scholar]
  36. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323 : 73–9. [Google Scholar]
  37. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk fracture in women with existing vertebral fractures. Lancet 1996; 348 : 1535–41. [Google Scholar]
  38. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk fracture in women with low bone density but without vertebral fracture. JAMA 1998; 280 : 2077–82. [Google Scholar]
  39. Pols HAP, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomised trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999; 9 : 461–8. [Google Scholar]
  40. Hosking D, Chilvers CED, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998; 338 : 485–92. [Google Scholar]
  41. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment vertebral and non vertebral fractures in women with postmenopausal osteoporosis. A randomised controlled trial. JAMA 1999; 282 : 1344–52. [Google Scholar]
  42. Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11 : 83–91. [Google Scholar]
  43. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344 : 333–40. [Google Scholar]
  44. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absoptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14 : 78–84. [Google Scholar]
  45. Delmas PD, Bjarnason NH, Mitlak BH, et al. The effects of raloxifene on bone mineral density, serum cholesterol, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337 : 1641–7. [Google Scholar]
  46. Johnston CC Jr, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women : three-year data from 2 doubleblind, randomized, placebo-controlled trials. Arch Intern Med 2000; 160 : 3444–50. [Google Scholar]
  47. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 1999; 282 : 637–45. [Google Scholar]
  48. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999; 281 : 2189–97. [Google Scholar]
  49. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene : 4-year results from the more trial. Multiples outcome of raloxifène evolution. Breast Cancer Res Treat 2001; 65 : 125–34. [Google Scholar]
  50. Chapuy MC, Arlot ME, Delmas PD, et al. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. Br Med J 1994; 308 : 1081–2. [Google Scholar]
  51. Meunier PJ, Sebert JL, Reginster JY, et al. Fluoride salt are no better at preventing new vertebral fractures than calcium-vitamin D in post-menopausal osteoporosis : the FAVOS study. Osteoporos Int 1998; 8 : 4–12. [Google Scholar]
  52. Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis : the prevent recurrence of osteoporotic fractures study. PROOF study group. Am J Med 2000; 109: 330–1. [Google Scholar]
  53. van Staa TP, Wegman S, de Vries F, et al. Use of statins and risk of fractures. JAMA 2001; 285 : 1850–5. [Google Scholar]
  54. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post-menopausal women with osteoporosis. N Engl J Med 2001; 344 : 1434–41. [Google Scholar]
  55. Mosekilde L. Sex differences in age-related changes in vertebral body size, density and biochemical competence in normal individuals. Bone 1990; 11 : 67–73. [Google Scholar]
  56. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343 : 604–10. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.